183 related articles for article (PubMed ID: 15876951)
41. Neonatal immunization: response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine.
Kurikka S; Käyhty H; Peltola H; Saarinen L; Eskola J; Mäkelä PH
Pediatrics; 1995 Jun; 95(6):815-22. PubMed ID: 7761204
[TBL] [Abstract][Full Text] [Related]
42. Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic.
Marshall H; McIntyre P; Roberton D; Dinan L; Hardt K
Int J Infect Dis; 2010 Jan; 14(1):e41-9. PubMed ID: 19467896
[TBL] [Abstract][Full Text] [Related]
43. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom.
Heath PT; Booy R; Azzopardi HJ; Slack MP; Bowen-Morris J; Griffiths H; Ramsay ME; Deeks JJ; Moxon ER
JAMA; 2000 Nov; 284(18):2334-40. PubMed ID: 11066183
[TBL] [Abstract][Full Text] [Related]
44. Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia.
Mulholland K; Suara RO; Siber G; Roberton D; Jaffar S; N'Jie J; Baden L; Thompson C; Anwaruddin R; Dinan L; Glezen WP; Francis N; Fritzell B; Greenwood BM
JAMA; 1996 Apr; 275(15):1182-8. PubMed ID: 8609686
[TBL] [Abstract][Full Text] [Related]
45. Antibody persistence for up to 5 years after a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) given at 12-15 months of age.
Marshall GS; Blatter M; Marchant C; Aris E; Mesaros N; Miller JM
Pediatr Infect Dis J; 2013 Jun; 32(6):662-8. PubMed ID: 23340564
[TBL] [Abstract][Full Text] [Related]
46. Enhanced antibody response in Venezuelan infants immunized with Haemophilus influenzae type b-tetanus toxoid conjugate vaccine.
Castillo de Febres O; Decker MD; Estopinan M; Bordones G; Edwards KM
Pediatr Infect Dis J; 1994 Jul; 13(7):635-9. PubMed ID: 7970953
[TBL] [Abstract][Full Text] [Related]
47. Five-year Antibody Persistence and Safety After a Single Dose of Combined Haemophilus influenzae Type B Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine in Haemophilus influenzae Type B-primed Toddlers.
Booy R; Nolan T; Reynolds G; Richmond P; Nissen M; Marshall H; Stoney T; Van Der Wielen M; Kolhe D; Miller JM
Pediatr Infect Dis J; 2015 Dec; 34(12):1379-84. PubMed ID: 26372451
[TBL] [Abstract][Full Text] [Related]
48. Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens.
Lagos R; Valenzuela MT; Levine OS; Losonsky GA; Erazo A; Wasserman SS; Levine MM
Lancet; 1998 May; 351(9114):1472-6. PubMed ID: 9605803
[TBL] [Abstract][Full Text] [Related]
49. Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines.
Omeñaca F; Arístegui J; Tejedor JC; Moreno-Perez D; Ruiz-Contreras J; Merino JM; Muro Brussi M; Sánchez-Tamayo T; Castro Fernandez J; Cabanillas L; Peddiraju K; Mesaros N; Miller JM
Pediatr Infect Dis J; 2011 Nov; 30(11):e216-24. PubMed ID: 21747321
[TBL] [Abstract][Full Text] [Related]
50. Haemophilus influenzae type b carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide-CRM197 (HbOC) conjugate vaccine.
Barbour ML; Booy R; Crook DW; Griffiths H; Chapel HM; Moxon ER; Mayon-White D
Pediatr Infect Dis J; 1993 Jun; 12(6):478-84. PubMed ID: 8345980
[TBL] [Abstract][Full Text] [Related]
51. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
[TBL] [Abstract][Full Text] [Related]
52. Immunogenicity of a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine.
Greenberg DP; Wong VK; Partridge S; Chang SJ; Jing J; Howe BJ; Ward JI
Pediatr Infect Dis J; 2000 Dec; 19(12):1135-40. PubMed ID: 11144372
[TBL] [Abstract][Full Text] [Related]
53. Immunologic response to Hib tetanus toxoid conjugated vaccine coadministered with DTPa either mixed or in two separate injections in toddlers not primed with Hib vaccine.
Meriste S; Jacquet JM; Willems P; Lutsar I
Hum Vaccin; 2008; 4(1):31-5. PubMed ID: 18438103
[TBL] [Abstract][Full Text] [Related]
54. Suppression and modulation of cellular and humoral immune responses to Haemophilus influenzae type B (Hib) conjugate vaccine in hib-diphtheria-tetanus toxoids-acellular pertussis combination vaccines: a study in a rat model.
Mawas F; Newman G; Burns S; Corbel MJ
J Infect Dis; 2005 Jan; 191(1):58-64. PubMed ID: 15593004
[TBL] [Abstract][Full Text] [Related]
55. Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four- and six-month-old infants.
Pichichero ME; Latiolais T; Bernstein DI; Hosbach P; Christian E; Vidor E; Meschievitz C; Daum RS
Pediatr Infect Dis J; 1997 Sep; 16(9):863-70. PubMed ID: 9306481
[TBL] [Abstract][Full Text] [Related]
56. A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants.
Pace D; Snape M; Westcar S; Hamaluba M; Yu LM; Begg N; Wysocki J; Czajka H; Maechler G; Boutriau D; Pollard AJ
Pediatr Infect Dis J; 2007 Nov; 26(11):1057-9. PubMed ID: 17984816
[TBL] [Abstract][Full Text] [Related]
57. Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy.
Pace D; Khatami A; Attard-Montalto S; Voysey M; Finn A; Faust SN; Heath PT; Borrow R; Snape MD; Pollard AJ
Vaccine; 2016 Dec; 34(50):6350-6357. PubMed ID: 28029540
[TBL] [Abstract][Full Text] [Related]
58. Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
Pace D; Khatami A; McKenna J; Campbell D; Attard-Montalto S; Birks J; Voysey M; White C; Finn A; Macloed E; Faust SN; Kent AL; Heath PT; Borrow R; Snape MD; Pollard AJ
BMJ; 2015 Apr; 350():h1554. PubMed ID: 25832102
[TBL] [Abstract][Full Text] [Related]
59. Immunogenicity and safety of two doses of catch-up immunization with Haemophilus influenzae type b conjugate vaccine in Indian children living with HIV.
Arya BK; Bhattacharya SD; Sutcliffe CG; Saha MK; Bhattacharyya S; Niyogi SK; Moss WJ; Panda S; Das RS; Mallick M; Mandal S
Vaccine; 2016 Apr; 34(19):2267-74. PubMed ID: 26988256
[TBL] [Abstract][Full Text] [Related]
60. RNA gene profile variation in peripheral blood mononuclear cells from rhesus macaques immunized with Hib conjugate vaccine, Hib capsular polysaccharide and TT carrier protein.
Tang J; Zhang Y; Zhang X; Liao Y; Wang Y; Ouyang S; Che Y; Xu M; Pu J; Shen Q; He Z; Ye Q; Li Q
BMC Immunol; 2018 Jan; 19(1):4. PubMed ID: 29368591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
